Seeding trial

Seeding trials are a type of clinical trial designed by pharmaceutical companies to promote a certain drug or medical device. These trials are often conducted after the drug or device has been approved by the FDA. The primary goal of a seeding trial is not to test the safety or efficacy of the product, but rather to encourage healthcare providers to prescribe or use the product in question.

Overview

Seeding trials are often disguised as legitimate scientific research, but their main purpose is to market the product. They are typically designed to maximize the exposure of the product to healthcare providers, with the hope that this exposure will lead to increased prescriptions or usage of the product. This is done by enrolling a large number of providers in the trial, who are then encouraged to prescribe or use the product with their patients.

Criticism

Seeding trials have been criticized for being unethical and potentially harmful to patients. Critics argue that these trials are not designed to contribute to medical knowledge, but rather to promote a product. Furthermore, they argue that patients enrolled in these trials may be exposed to unnecessary risks, as the safety and efficacy of the product may not have been fully established.

Legal implications

In some cases, pharmaceutical companies have faced legal action as a result of seeding trials. For example, in 2009, the pharmaceutical company Pfizer agreed to pay $2.3 billion to settle allegations that it had conducted a seeding trial for its painkiller Bextra, which was later withdrawn from the market due to safety concerns.

See also

• Clinical trial
• Pharmaceutical industry
• Marketing ethics